Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dynavax Announces Acceptance of Two Data Abstracts for SD-101 in Combination with KEYTRUDA® for Presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting
Data from Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Durability Data in Advanced Metastatic Melanoma BERKELEY, Calif. , March 15, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that data from an ongoing Phase 1b/2 study
View HTML
Toggle Summary Dynavax Reports Fourth Quarter and Year End 2017 Financial Results
HEPLISAV-B Launched in the United States Phase 2 Data in Two Immuno-oncology Programs Planned for First Half 2018 BERKELEY, Calif. , March 08, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today reported financial results for the fourth quarter and year ended December 31,
View HTML
Toggle Summary Dynavax to Present at the Cowen & Co. Annual Health Care Conference
BERKELEY, Calif. , March 05, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that Eddie Gray , Dynavax’s Chief Executive Officer, will present at the Cowen & Co. 38 th Annual Health Care Conference in Boston, MA.
View HTML
Toggle Summary Stanley A. Plotkin, M.D. Steps Down from Board of Dynavax Technologies
Dr. Plotkin Will Continue as Scientific Advisor BERKELEY, Calif. , March 02, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (“Dynavax”) (NASDAQ:DVAX) announced today that Stanley A. Plotkin , M.D. has indicated his intention to step down from the Board of Directors (“Board”) effective
View HTML
Toggle Summary Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BERKELEY, Calif. , March 01, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that on March 1, 2018 the Compensation Committee of Dynavax’s Board of Directors approved the grant of inducement stock options to purchase an aggregate of 30,000 shares of common
View HTML
Toggle Summary Dynavax's HEPLISAV-B™ [Hepatitis B Vaccine (Recombinant), Adjuvanted] Recommended by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults
HEPLISAV-B is the First and Only Two-Dose Vaccine in the U.S. for Hepatitis B Prevention in Adults
View HTML
Toggle Summary Dynavax Secures $175 Million in Non-Dilutive Debt Financing
Proceeds to be Used to Commercialize HEPLISAV-B™ [Hepatitis B Vaccine (Recombinant), Adjuvanted] in United States and Advance Company's Immuno-Oncology Product Candidates Company Deploying HEPLISAV-B Field Sales Team BERKELEY, Calif. , Feb. 20, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies
View HTML
Toggle Summary Dynavax to Present at the RBC Capital Markets Global Healthcare Conference
BERKELEY, Calif. , Feb. 14, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that Eddie Gray , Dynavax's chief executive officer, will participate in a fireside chat at the 2018 RBC Capital Markets Global Healthcare Conference in New York City .
View HTML
Toggle Summary Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BERKELEY, Calif. , Feb. 02, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that on February 1, 2018 the Compensation Committee of Dynavax's Board of Directors approved the grant of (i) inducement stock options to purchase an aggregate 98,000 shares of common
View HTML
Toggle Summary Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BERKELEY, Calif. , Jan. 12, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that on January 10, 2018 the Compensation Committee of Dynavax's Board of Directors approved the grant of inducement stock options to purchase an aggregate of 57,000 shares of common
View HTML